STRS Ohio’s Black Diamond Therapeutics BDTX Stock Holding History

STRS Ohio’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,100	Closed	-$77K	–	2162
2020 Q1	$77K	Buy	+3,100	New	+$94.3K	﹤0.01%	1722

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

STRS Ohio's BDTX Position: Q2 2020 in Review

STRS Ohio sold out of Black Diamond Therapeutics (BDTX) in Q2 2020, closing a stake of 3,100 shares — an estimated $77K sold.

STRS Ohio first reported a position in BDTX in Q1 2020 and held it in 1 quarter. The position peaked at $77K in Q1 2020. 80 funds tracked by Wall St. Rank hold BDTX as of Q2 2020.

STRS Ohio reported no remaining Black Diamond Therapeutics position as of Q2 2020 after selling out during the quarter.
STRS Ohio sold 3,100 Black Diamond Therapeutics shares in Q2 2020, an estimated $77K.
STRS Ohio first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 1 quarter.
STRS Ohio's Black Diamond Therapeutics position peaked at $77K in Q1 2020.
80 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2020.

Based on STRS Ohio's 13F filing for Q2 2020, filed 23 Jul 2020.